share_log

Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $46

Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $46

派珀·桑德勒維持對Supernus Pharmicals的增持,將目標價上調至46美元
Benzinga ·  2023/05/10 09:36

Piper Sandler analyst David Amsellem maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the price target from $45 to $46.

派珀·桑德勒分析師戴維·阿姆塞勒姆維持Supernus Pharmicals(納斯達克股票代碼:SUPN)的增持,並將目標股價從45美元上調至46美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論